BETHLEHEM, Pa., May 02, 2017 -- Furthering its efforts to enhancing patient, clinician and environmental safety, B. Braun Medical Inc. will debut ReadyFor800.com at The Oncology Nursing Society’s Annual Conference, May 4-7 in Denver, Colorado. The new online educational resource will focus on the awareness and implementation of the new hazardous drug safety standard, USP <800>.
“These medications can save the lives of patients, but they also pose risk to our healthcare professionals,” said Tom Sutton, Vice President of Vascular Access Systems at B. Braun. “As one of the leading suppliers of Closed System Transfer Devices (CSTDs) in the United States, B. Braun takes responsibility to help nurses and other healthcare workers proactively protect not only their patients, but also themselves and their coworkers.”
ReadyFor800.com details the risks for healthcare personnel and introduces implementation plans and protocols to ensure the best protection possible from hazardous drug exposure. Supported by expert insight, experience, and recommendations, and told from the pharmacy, nursing and management perspectives, ReadyFor800.com is a comprehensive tool for educating staff and colleagues. It provides a blue print to help implement USP <800> in hospital or outpatient facilities.
At ONS 2017, attendees can visit B. Braun booth #925 to experience ReadyFor800.com. Attendees can gain an understanding of the risks involved in the compounding and administering of hazardous drugs, and discuss the steps required for USP <800> compliance with ONS Connect contributing editor Seth Eisenberg, RN, ASN, OCN®, BMTCN™.
About USP <800>
USP <800> was published on February 1, 2016 with an implementation date of July 1, 2018. The chapter describes practice and quality standards for the handling of hazardous drugs, including transport, storage, preparation, and administration, in healthcare settings to help promote patient safety, worker safety, and environmental protection. USP <800> applies to all healthcare personnel – such as pharmacists, technicians, nurses, physicians, physician assistants, home healthcare workers, veterinarians, and veterinary technicians – as well as all facilities associated with the handling of hazardous drugs.
About B. Braun
B. Braun Medical Inc., a market leader in Closed System Drug Transfer Devices, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. The OnGuard® CSTD from B. Braun is designed to help protect healthcare workers within the pharmacy and specifically during nursing administration of hazardous drugs. OnGuard meets the NIOSH, ASHP, and ONS definitions of a CSTD, along with all proposed USP <800> requirements.
To learn more about B. Braun Medical or OnGuard CSTD, visit www.BBraunUSA.com.
Contact: Jason Ford B. Braun Medical Inc. 610.997.4722 [email protected]


Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 



